Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GW Pharma set to standout in a blockbuster year for British drug makers

British firms are responsible for four of twelve potential potential new blockbuster drugs due for approval this year
drugs, pills, pharmaceuticals
GW Pharma has developed a treatment for a severe form of epilepsy.

This is the year is expected to be a blockbuster with 12 new drugs set for approval that have the potential to achieve peak sales in excess of US$1bn a year.

According to researchers at Clarivate Analytics, 46 new treatments are slated for US Food & Drug Administration over that period.

The biggest of the bunch is expected to be Hemlibra, an injection for haemophilia that is expected to generate annual revenues of US$4bn by 2022 for its maker, Roche.

That’s still some way short of AbbVie’s Humira (for arthritis) and Gilead’s hepatitis C drug Harvoni, which generated US$14b of sales each last year. But these sorts of products are a rarity as are the common or garden variety blockbuster drug with annual sales of US$1bn or more.

That said, the 2018 pipeline appears to have more promise than previous years. In fact, it is the best result in five years.

READ: GlaxoSmithKline winning over City number crunchers

Four UK companies figure in the Clarivate top-12 with Shingrix, developed for shingles by GlaxoSmithKline, at number-five in the list and Shire’s Lanadelumab, for facial swelling called angiodema, in ninth place.

The award for best of British should go to GW Pharma (LON:GWP), which has developed a treatment for a severe and to date untreatable form of epilepsy.

READ: GW Pharma posts more good data from epilepsy trials

While the Cambridge-based group is now listed solely on NASDAQ in the US, primarily a stock exchange for technology companies, it spent its formative years tapping UK investors for growth capital as a member of the AIM exchange in London.

It should be pointed out GW is delivering a breakthrough in that its product, Epidiolex, will be the first cannabis-based treatment to be approved by the FDA. Its peak sales are put at just under US$1.2bn.

Finally, while it has been a tough year for Indivior with the threat of copycat competition to its best-selling heroin substitute, in Sublocade it may have come up with a money-spinning replacement. It is expected to make around US$1.1bn by 2022.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

cancer
July 11 2018
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
syringe
June 20 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use